Marks designated
®
and
™
are owned by Shire or an affi liated company.
©2016 Shire US Inc. Lexington, MA 02421 S24434 11/16
Please see the adjacent page for Brief Summary of Safety Information
and visit Xiidra-ECP.com for Full Prescribing Information.
Indication
Xiidra
®
(lifi tegrast ophthalmic solution) 5% is indicated for the treatment
of signs and symptoms of dry eye disease (DED).
Important Safety Information
In clinical trials, the most common adverse reactions reported in 5-25%
of patients were instillation site irritation, dysgeusia and reduced visual
acuity. Other adverse reactions reported in 1% to 5% of the patients were
blurred vision, conjunctival hyperemia, eye irritation, headache, increased
lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution,
patients should not touch the tip of the single-use container to their
eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra
and may be reinserted 15 minutes following administration.
Safety and effi cacy in pediatric patients below the age of 17 years have
not been established.
Reference: 1. FDA approves new medication for
dry eye disease. FDA News Release. July 2016.
http://www.fda.gov/newsevents/newsroom/
pressannouncements/ucm510720.htm. Accessed
July 12, 2016.
Xiidra is a lymphocyte
function-associated antigen-1
(LFA-1) antagonist, the fi rst
medication in a new class
of drugs.
1
Check it out at Xiidra-ECP.com
The fi rst prescription eye drop FDA-approved to treat
both the signs and symptoms of Dry Eye Disease
BIIG DEAL
Kind of a